Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 8/20 | 0.43 |
| ▸ | CA2 | P00918 | 8/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | MET | P08581 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9002486 | 0.80 | RECQL (0.48) | RECQLNPC1RAB9AGFERCA1 | |
| SCHEMBL27570548 | 0.77 | RECQL (0.48) | RECQLNPC1RAB9AGFERCA1 | |
| SCHEMBL6935649 | 0.76 | RECQL (0.44) | RECQLNPC1RAB9AGFERCA1 | |
| SCHEMBL3235233 | 0.74 | NPC1 (0.57) | RECQLNPC1RAB9AGFERCA1 | |
| SCHEMBL28833034 | 0.72 | CA1 (0.33) | CA1CA2CA9CA12CA6 | |
| Sulfuric Acid SCHEMBL8642565 | 0.71 | GFER (0.70) | RECQLGFERCA1CA2CA9 | |
| SCHEMBL30694096 | 0.69 | NPC1 (0.56) | NPC1RAB9AGFERCA1CA2 | |
| SCHEMBL2540602 | 0.69 | NPC1 (0.56) | NPC1RAB9AGFERCA1CA2 | |
| SCHEMBL21524969 | 0.69 | CA1 (0.48) | RECQLGFERCA1CA2CA9 | |
| SCHEMBL27735738 | 0.68 | GFER (0.65) | RECQLNPC1RAB9AGFERMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735589-B2 | Process for the synthesis of naratriptan | CIPLA LIMITED (IN) | 2014-05-27 | — | — | US | disclosed |
| EP-2467373-B1 | A PROCESS FOR THE SYNTHESIS OF NARATRIPTAN | CIPLA LTD (IN) | 2013-10-02 | — | — | EP | disclosed |
| US-20120220778-A1 | Process for the synthesis of naratriptan | CIPLA LIMITED (IN) | 2012-08-30 | — | — | US | disclosed |
| EP-2467373-A2 | A PROCESS FOR THE SYNTHESIS OF NARATRIPTAN | Cipla Limited (IN) | 2012-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220778-A1 | Process for the synthesis of naratriptan | ZFR, SPR, NPSR1 | RECQL 4763/4885NPC1 396/4885RAB9A 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.